01—Abstract
Summary
Summary of the 8-K filed July 2, 2025. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (the Company) disclosed in a Form 8-K that on June 27, 2025 (the Closing Date), it and its subsidiary Eidos Therapeutics, Inc. entered into a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP as purchasers.
Under the agreement, Eidos sold to the purchasers certain rights to receive royalty payments on net sales of acoramidis-containing products in the European Union and European Patent Organization member and extension states, arising under the Bayer License Agreement and an amended and restated license with BridgeBio International GmbH. The purchasers agreed to pay Eidos $300 milliona in cash, funded in full on the Closing Date. The purchased royalty rights are subject to an annual cap equal to 60% of royalty payments paid by Bayer on the first $500,000,000 of annual net sales of Licensed Products in the Licensed Territory under the Bayer License Agreement, and an initial hard cap equal to 145% of the Purchase Price.
The Company and Eidos granted the purchaser representative a security interest in specific assets related to the purchased royalties. The filing also states that upon a change of control of the Company, a successor entity may either assume the obligations under the Purchase Agreement or pay the purchasers an Adjusted Amount, after which no further payments would be due. The complete agreement is to be filed as an exhibit to a subsequent periodic report.
02—Key points
Key Highlights
- Eidos Therapeutics sold certain royalty payment rights on acoramidis net sales in the EU and European Patent Organization states to Acoramidis Royalty SPV, LP and LSI Financing Fund, LP.
- Purchasers paid $300 million in cash, funded in full on June 27, 2025.
- Purchased royalties are subject to an annual cap of 60% of Bayer royalty payments on the first $500,000,000 of annual net sales, and an initial hard cap of 145% of the Purchase Price.
- The Company and Eidos granted a security interest in specific assets related to the purchased royalty payments to the purchaser representative.
- Upon a change of control, the successor may assume the agreement or pay the purchasers the Adjusted Amount to end further payment obligations.
- The transaction is reported under Item 1.01 (material definitive agreement) and Item 2.03 (direct financial obligation), with the full agreement to be filed in a later periodic report.
03—Questions
Frequently Asked Questions
What did BridgeBio and Eidos receive in this transaction?
The filing states that the purchasers agreed to pay Eidos $300 million in cash, which was funded in full on the Closing Date of June 27, 2025.
What rights were sold to the purchasers?
Eidos sold certain of its rights to receive specified royalty payments on net sales of certain acoramidis-containing products made in the European Union and all member and extension states of the European Patent Organization, under the Bayer License Agreement and an amended and restated license with BridgeBio International GmbH.
What limits apply to the royalty payments owed to the purchasers?
The purchasers' rights are subject to an annual cap equal to 60% of all royalty payments paid by Bayer under the Bayer License Agreement on the first $500,000,000 of annual net sales in the Licensed Territory, and an initial hard cap equal to 145% of the Purchase Price.
Is the transaction secured by any collateral?
Yes. The Company and Eidos granted the Purchaser Representative, for the benefit of the Purchasers, a security interest in specific assets related to the Purchased Royalty Payment.
What happens if BridgeBio undergoes a change of control?
The successor entity may either assume the obligations of the Company and/or Eidos under the Purchase Agreement or pay the Purchasers the Adjusted Amount, after which no further payments would be due to the Purchasers or the Purchaser Representative.
04—Continue